Casdozokitug clinical trials
Also written CHS-388.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses casdozokitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coherus Oncology, Inc. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test casdozokitug.
Studies
Open first, then newest update. How each study uses casdozokitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaTerminatedPhase 2Coherus Oncology, Inc.NCT05359861Written as CasdozokitugHow we know
- A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaActive, not recruitingPhase 2Coherus Oncology, Inc.NCT06679985Written as CasdozokitugHow we know
- Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsCompletedPhase 1Coherus Oncology, Inc.NCT04374877Written as CHS-388How we know
Codes
What other systems call casdozokitug · ClinicalTrials.gg INT016015
- UNII (FDA) AL6I5N2HTNCASDOZOKITUGOne source FDA
- NCI Thesaurus C174410CasdozokitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AL6I5N2HTN | CASDOZOKITUG | One source FDA |
| NCI Thesaurus | C174410 | Casdozokitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.